Home » Reports » USA Broker Ratings » Inogen Inc 25.9% Potential Upside Now Implied by Stifel

Inogen Inc 25.9% Potential Upside Now Implied by Stifel

Inogen Inc with TICKER NASDAQ:INGN had its stock rating noted as ‘Reiterated’ with the recommendation being set at ‘BUY’ this morning by analysts at Stifel. Inogen Inc are listed in the Health Care sector within NASDAQ. Stifel have set their target price at 68 USD on its stock. This would imply the analyst believes there is a potential upside of 25.9% from the opening price of 54.01 USD.

Inogen Inc NASDAQ:INGN has a 50 day moving average of 48.53 USD and a 200 Day Moving Average share price is recorded at 39.19 USD. The 1 year high share price is 55.98 USD while the year low stock price is currently 19.16 USD. Over the last 30 and 90 trading days the company share price has increased 11.49 points and increased 17.11 points respectively. There are currently 19,446,700 shares in issue with the average daily volume traded being 323,349. Market capitalisation for NASDAQ:INGN is $1,039,037,187.00 USD.


Inogen Inc NASDAQ:INGN is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company offers Inogen One systems, such as Inogen One G3 and G2 that concentrate the air around the patients to offer a single source of supplemental oxygen. The Inogen One G3 and G2 have up to 4.5 and five hours of battery life respectively. The Company’s Inogen One G2 is effective for nocturnal use.

Join us on our new LinkedIn page

Follow us on LinkedIn